Table 4.
Number of cases/total number of subjects | Model 1 | Model 2 | Model 3 | Model 4 | |||||
---|---|---|---|---|---|---|---|---|---|
OR/unit (95% CI) | P | OR/unit (95% CI) | P | OR/unit (95% CI) | P | OR/unit (95% CI) | P | ||
IR (HOMA-IR ≥ 3.0) | 73/352 | 1.42 (1.08–1.86) | 0.011 | 1.44 (1.07-1.92) | 0.015 | 1.36 (1.02–1.81) | 0.039 | 1.35 (1.01–1.81) | 0.049 |
Central obesity | 152/352 | 1.20 (0.95–1.50) | 0.125 | 1.25 (0.99-1.57) | 0.065 | 1.00 (0.74–1.35) | 0.979 | 1.00 (0.74–1.34) | 0.974 |
Elevated blood pressure | 75/352 | 1.38 (1.07–1.76) | 0.012 | 1.46 (1.08-1.99) | 0.015 | 1.38 (1.01–1.91) | 0.049 | 1.33 (1.01–1.76) | 0.046 |
Reduced HDL-C | 58/352 | 1.08 (0.80–1.47) | 0.612 | 1.05 (0.77-1.45) | 0.756 | 1.09 (0.78–1.52) | 0.609 | 1.04 (0.75–1.43) | 0.830 |
Elevated TG | 61/352 | 1.83 (1.40–2.41) | < 0.001 | 1.76 (1.33-2.33) | < 0.001 | 1.54 (1.14–2.07) | 0.004 | 1.70 (1.28–2.26) | < 0.001 |
Hyperglycemia | 44/352 | 1.49 (1.11–1.99) | 0.008 | 1.48 (1.10-1.98) | 0.009 | 1.55 (1.14–2.09) | 0.005 | 1.51 (1.12–2.03) | 0.007 |
OR indicates odds ratio for per 10 μg/ml (approximately 1 SD) increase in baseline RBP4 levels
BMI body mass index, HOMA-IR homeostatic model assessment of insulin resistance, IR insulin resistance, TG triglycerides, HDL-C high-density lipoprotein cholesterol, MS metabolic syndrome
Model 1: adjusted for age, gender and pubertal stage at baseline
Model 2: Model 1 + additionally adjusted with physical activity, dietary score, and baseline BMI (except central obesity model)
Model 3: Model 2 + additionally adjusted with levels of the individual components at baseline
Model 4: Model 1 + additionally adjusted with adiponectin, leptin levels and BMI at baseline